Tredje AP-fonden’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $24.4M | Buy |
270,072
+94,499
| +54% | +$7.92M | 0.11% | 200 |
|
|
2026
Q1 | $14.1M | Buy |
+175,573
| New | +$14.5M | 0.08% | 247 |
|
|
2024
Q4 | – | Sell |
-61,000
| Closed | -$4.03M | – | 480 |
|
|
2024
Q3 | $4.03M | Sell |
61,000
-133,156
| -69% | -$9.67M | 0.04% | 234 |
|
|
2024
Q2 | $17.9M | Sell |
194,156
-22,000
| -10% | -$1.95M | 0.17% | 102 |
|
|
2024
Q1 | $20.7M | Buy |
216,156
+47,000
| +28% | +$3.95M | 0.21% | 93 |
|
|
2023
Q4 | $12.9M | Buy |
169,156
+24,500
| +17% | +$1.7M | 0.16% | 107 |
|
|
2023
Q3 | $10M | Sell |
144,656
-8,029
| -5% | -$645K | 0.15% | 107 |
|
|
2023
Q2 | $14.4M | Sell |
152,685
-40,820
| -21% | -$3.55M | 0.2% | 97 |
|
|
2023
Q1 | $16M | Buy |
193,505
+41,216
| +27% | +$3.24M | 0.25% | 92 |
|
|
2022
Q4 | $11.4M | Buy |
152,289
+90,383
| +146% | +$6.97M | 0.19% | 101 |
|
|
2022
Q3 | $5.12M | Sell |
61,906
-52,733
| -46% | -$5.07M | 0.11% | 148 |
|
|
2022
Q2 | $10.9M | Hold |
114,639
| – | – | 0.27% | 83 |
|
|
2022
Q1 | $13.5M | Buy |
114,639
+24,400
| +27% | +$2.74M | 0.27% | 80 |
|
|
2021
Q4 | $11.7M | Buy |
90,239
+8,239
| +10% | +$961K | 0.23% | 95 |
|
|
2021
Q3 | $9.28M | Buy |
82,000
+55,500
| +209% | +$6.33M | 0.19% | 110 |
|
|
2021
Q2 | $2.75M | Hold |
26,500
| – | – | 0.06% | 166 |
|
|
2021
Q1 | $2.22M | Hold |
26,500
| – | – | 0.05% | 176 |
|
|
2020
Q4 | $2.42M | Sell |
26,500
-162,662
| -86% | -$13.5M | 0.06% | 164 |
|
|
2020
Q3 | $15.1M | Hold |
189,162
| – | – | 0.49% | 52 |
|
|
2020
Q2 | $13.1M | Hold |
189,162
| – | – | 0.54% | 47 |
|
|
2020
Q1 | $11.9M | Buy |
189,162
+136,998
| +263% | +$9.88M | 0.62% | 43 |
|
|
2019
Q4 | $4.06M | Sell |
52,164
-2,478
| -5% | -$193K | 0.21% | 125 |
|
|
2019
Q3 | $4M | Sell |
54,642
-4,758
| -8% | -$334K | 0.19% | 138 |
|
|
2019
Q2 | $3.66M | Sell |
59,400
-3,648
| -6% | -$221K | 0.17% | 148 |
|
|
2019
Q1 | $4.02M | Buy |
63,048
+14,901
| +31% | +$850K | 0.21% | 124 |
|
|
2018
Q4 | $2.46M | Buy |
48,147
+2,730
| +6% | +$138K | 0.15% | 165 |
|
|
2018
Q3 | $2.64M | Buy |
45,417
+7,260
| +19% | +$355K | 0.13% | 194 |
|
|
2018
Q2 | $1.85M | Sell |
38,157
-21,708
| -36% | -$1.01M | 0.06% | 293 |
|
|
2018
Q1 | $2.78M | Sell |
59,865
-450
| -0.7% | -$19.5K | 0.1% | 248 |
|
|
2017
Q4 | $2.27M | Sell |
60,315
-390
| -0.6% | -$14.3K | 0.08% | 290 |
|
|
2017
Q3 | $2.21M | Sell |
60,705
-13,170
| -18% | -$502K | 0.08% | 295 |
|
|
2017
Q2 | $2.91M | Sell |
73,875
-19,500
| -21% | -$712K | 0.11% | 231 |
|
|
2017
Q1 | $2.93M | Sell |
93,375
-24,639
| -21% | -$771K | 0.12% | 232 |
|
|
2016
Q4 | $3.69M | Buy |
118,014
+9,066
| +8% | +$294K | 0.16% | 181 |
|
|
2016
Q3 | $4.38M | Buy |
108,948
+18,102
| +20% | +$682K | 0.2% | 126 |
|
|
2016
Q2 | $3.02M | Buy |
90,846
+87,426
| +2,556% | +$2.99M | 0.14% | 172 |
|
|
2016
Q1 | $120K | Buy |
+3,420
| New | +$94.4K | 0.01% | 381 |
|
Other funds holding EW
Tredje AP-fonden's EW Position: Q2 2026 in Review
Tredje AP-fonden increased its Edwards Lifesciences (EW) stake by 54% in Q2 2026, buying an estimated $7.92M and bringing the position to 270,072 shares worth $24.4M. The position accounts for 0.11% of the portfolio, ranked #200.
Tredje AP-fonden first reported a position in EW in Q1 2016 and has held it in 37 quarters since. 1,325 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- Tredje AP-fonden held 270,072 shares of Edwards Lifesciences worth $24.4M as of Q2 2026.
- Tredje AP-fonden bought 94,499 Edwards Lifesciences shares in Q2 2026, an estimated $7.92M.
- Edwards Lifesciences made up 0.11% of Tredje AP-fonden's portfolio in Q2 2026, its #200 holding.
- Tredje AP-fonden first reported a position in Edwards Lifesciences in Q1 2016 and has held it in 37 quarters since.
- 1,325 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on Tredje AP-fonden's 13F filing for Q2 2026, filed 10 Aug 2026.